EP2097093A4 - Therapeutische und diagnostische peptide - Google Patents
Therapeutische und diagnostische peptideInfo
- Publication number
- EP2097093A4 EP2097093A4 EP07869233A EP07869233A EP2097093A4 EP 2097093 A4 EP2097093 A4 EP 2097093A4 EP 07869233 A EP07869233 A EP 07869233A EP 07869233 A EP07869233 A EP 07869233A EP 2097093 A4 EP2097093 A4 EP 2097093A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- therapeutic
- diagnostic purposes
- peptides used
- peptides
- diagnostic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86986506P | 2006-12-13 | 2006-12-13 | |
| US97405607P | 2007-09-20 | 2007-09-20 | |
| US11/955,226 US7811995B2 (en) | 2006-12-13 | 2007-12-12 | Therapeutic and diagnostic peptides |
| PCT/US2007/087425 WO2008076824A2 (en) | 2006-12-13 | 2007-12-13 | Therapeutic and diagnostic peptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP2097093A2 EP2097093A2 (de) | 2009-09-09 |
| EP2097093A4 true EP2097093A4 (de) | 2010-06-09 |
| EP2097093B1 EP2097093B1 (de) | 2016-02-17 |
Family
ID=39536989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP07869233.2A Active EP2097093B1 (de) | 2006-12-13 | 2007-12-13 | Therapeutische und diagnostische peptide |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7811995B2 (de) |
| EP (1) | EP2097093B1 (de) |
| JP (1) | JP5421116B2 (de) |
| DK (1) | DK2097093T3 (de) |
| ES (1) | ES2567142T3 (de) |
| WO (1) | WO2008076824A2 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8496942B2 (en) * | 2006-12-13 | 2013-07-30 | Susavion Biosciences, Inc. | Therapeutic peptides and uses thereof |
| US20150299255A1 (en) * | 2010-11-01 | 2015-10-22 | Susavion Biosciences, Inc. | Compositions and methods for modulating innate and adaptive immune systems |
| WO2013096829A2 (en) * | 2011-12-22 | 2013-06-27 | Arizona Biomedical Research Commission | Activation of cellular assault processes in the treatment of glioblastoma multiforme |
| US10350260B2 (en) * | 2015-04-27 | 2019-07-16 | Susavion Biosciences, Inc. | Compositions and methods for treating cancer and persistent viral infections |
| JP6740250B2 (ja) * | 2015-04-27 | 2020-08-12 | スサヴィオン バイオサイエンシーズ インコーポレイテッド | がんおよび持続性ウイルス感染を処置するための組成物および方法 |
| WO2020036987A1 (en) | 2018-08-13 | 2020-02-20 | Signablok, Inc. | Peptides and compositions for targeted treatment and imaging |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6193981B1 (en) * | 1997-07-11 | 2001-02-27 | Thymon L.L.C. | Methods and compositions for impairing multiplication of HIV-1 |
| WO2003091275A2 (en) * | 2002-04-23 | 2003-11-06 | Andrea Savarino | Compositions containing anti-hiv peptides and methods of use |
| WO2005087793A2 (en) * | 2004-02-05 | 2005-09-22 | The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University | Immunostimulatory compositions and uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1105777C (zh) * | 1993-03-08 | 2003-04-16 | 藤泽药品工业株式会社 | 由氧化葡糖杆菌t－100得到的l－山梨糖脱氢酶及其制备方法 |
| US5641747A (en) | 1994-07-25 | 1997-06-24 | Temple University-Of The Commonwealth System Of Higher Education | Treatment of osteopetrotic diseases |
| US6410269B1 (en) | 1995-06-07 | 2002-06-25 | Nobuto Yamamoto | Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis |
| GB9714680D0 (en) * | 1997-07-11 | 1997-09-17 | Medical Res Council | Recombinant production of proteins |
| US6551795B1 (en) | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
| WO2000031130A1 (en) | 1998-11-20 | 2000-06-02 | Bio Merieux | Synthetic polypeptides corresponding to the hepatitis c virus (hcv) and applications |
| CA2290722A1 (en) * | 1999-12-08 | 2001-06-08 | Glen C. Macdonald | Consensus peptide presenting entities |
| US20110131679A2 (en) * | 2000-04-19 | 2011-06-02 | Thomas La Rosa | Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
| CA2426154A1 (en) | 2000-11-09 | 2002-08-01 | Northeastern Ohio Universities College Of Medicine | Agents and methods for promoting bone growth |
| GB0112126D0 (en) | 2001-05-18 | 2001-07-11 | Allergene Inc | Composition |
| WO2003061589A2 (en) | 2002-01-23 | 2003-07-31 | Cel-Sci Corporation | Methods for treating diseases or conditions with peptide constructs |
| US7351693B2 (en) | 2002-01-25 | 2008-04-01 | University Court Of The University Of Aberdeen | Peptides and nucleic acids of the cathelicidin family, derived from fish, and uses thereof |
| AU2003220188A1 (en) | 2002-03-11 | 2003-09-29 | President And Fellows Of Harvard College | Detection and quantification of modified proteins |
| WO2004011650A2 (en) | 2002-07-24 | 2004-02-05 | Intercell Ag | Antigens encoded by alternative reading frame from pathogenic viruses |
| US20050063937A1 (en) | 2003-09-16 | 2005-03-24 | Cheng Li | Multiple-arm peptide compounds, methods of manufacture and use in therapy |
| JP2008522951A (ja) | 2004-07-19 | 2008-07-03 | ベイラー・カレツジ・オブ・メデイシン | サイトカインシグナル伝達調節物質の調節および免疫療法のための応用 |
| US20060078535A1 (en) * | 2004-10-13 | 2006-04-13 | The Regents Of The University Of Michigan | Anticancer compounds and methods |
| US8178649B2 (en) | 2004-12-07 | 2012-05-15 | Arizona Biomedical Research Commission | Immunostimulatory compositions and uses thereof |
-
2007
- 2007-12-12 US US11/955,226 patent/US7811995B2/en active Active
- 2007-12-13 DK DK07869233.2T patent/DK2097093T3/en active
- 2007-12-13 EP EP07869233.2A patent/EP2097093B1/de active Active
- 2007-12-13 ES ES07869233.2T patent/ES2567142T3/es active Active
- 2007-12-13 JP JP2009541593A patent/JP5421116B2/ja not_active Expired - Fee Related
- 2007-12-13 WO PCT/US2007/087425 patent/WO2008076824A2/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6193981B1 (en) * | 1997-07-11 | 2001-02-27 | Thymon L.L.C. | Methods and compositions for impairing multiplication of HIV-1 |
| WO2003091275A2 (en) * | 2002-04-23 | 2003-11-06 | Andrea Savarino | Compositions containing anti-hiv peptides and methods of use |
| WO2005087793A2 (en) * | 2004-02-05 | 2005-09-22 | The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University | Immunostimulatory compositions and uses thereof |
Non-Patent Citations (4)
| Title |
|---|
| AKIRA MANKI ET AL: "VACCINATION WITH MULTIPLE ANTIGEN PEPTIDE AS REJECTION ANTIGEN PEPTIDE IN MURINE LEUKEMIA", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER REREARCH, US, vol. 58, no. 9, 1 May 1998 (1998-05-01), pages 1960 - 1964, XP001010552, ISSN: 0008-5472 * |
| CHARGELEGUE DANIEL ET AL: "A peptide mimic of a protective epitope of respiratory syncytial virus selected from a combinatorial library induces virus-neutralizing antibodies and reduces viral load in vivo", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 72, no. 3, 1 March 1998 (1998-03-01), pages 2040 - 2046, XP002175660, ISSN: 0022-538X * |
| CHERSI A ET AL: "Specificities of rabbit antisera to multiple antigen (MAP) peptides", ZEITSCHRIFT FUER NATURFORSCHUNG. C, A JOURNAL OF BIOSCIENCES, TUEBINGEN, DE, vol. 50, no. 9-10, 1 September 1995 (1995-09-01), pages 735 - 738, XP009132917, ISSN: 0939-5075 * |
| NICOLAUS B J R: "SYMBIOTIC APPROACH TO DRUG DESIGN", DECISION MAKING IN DRUG RESEARCH, XX, XX, 1 January 1983 (1983-01-01), pages 173 - 186, XP001111439 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008076824A3 (en) | 2008-11-06 |
| JP2010513310A (ja) | 2010-04-30 |
| US20080292650A1 (en) | 2008-11-27 |
| US7811995B2 (en) | 2010-10-12 |
| EP2097093B1 (de) | 2016-02-17 |
| DK2097093T3 (en) | 2016-04-25 |
| ES2567142T3 (es) | 2016-04-20 |
| JP5421116B2 (ja) | 2014-02-19 |
| EP2097093A2 (de) | 2009-09-09 |
| WO2008076824A2 (en) | 2008-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2023002I1 (el) | Συνθεσεις και χρησεις για αντιμετωπιση πολλαπλης σκληρυνσης | |
| LTPA2018006I1 (lt) | Pakeistųjų oksazolidinonų kombinuota terapija | |
| EP2068693A4 (de) | Endoskopische verfahren und vorrichtungen für transnasale eingriffe | |
| EP2068997A4 (de) | Endoskopische verfahren und vorrichtungen für transnasale eingriffe | |
| EP2056931A4 (de) | Gerät und verfahren zur abgabe von transvenösen leitungen | |
| EP2120749A4 (de) | Andrück-pedikelschraubenanordnung | |
| DK1959991T3 (da) | Terapeutisk vaccine | |
| BRPI0807544A2 (pt) | Sólido farmacêutico e dose de vacina | |
| BRPI0714539A2 (pt) | "formas farmacêuticas" | |
| PT2186889E (pt) | Péptido cdca1 e agente farmacêutico que o compreende | |
| FI20095180A7 (fi) | Lääketieteellinen harjoituslaite | |
| DE602007012954D1 (de) | Ultraschalloperationsvorrichtung | |
| DE502006007776D1 (de) | Endoskopisches Chirurgiegerät | |
| PL3424932T3 (pl) | Boronoftalidy do zastosowania terapeutycznego | |
| DE602007014130D1 (de) | Ultraschallendoskop | |
| EP2189100A4 (de) | Medizinisches gerät | |
| EP1992348A4 (de) | Pharmazeutische kombination | |
| CR10571A (es) | Vacuna virica recombinante | |
| HUE062920T2 (hu) | Eljárások vakcina beadására | |
| BRPI0912768A2 (pt) | vacinas de poliproteínas recombinante para o tratamento e diagnóstico de leishmaniose | |
| EP2155231A4 (de) | Bilddarstellung und behandlung von virus-assoziierten tumoren | |
| DE602007000485D1 (de) | Diagnostisches Ultraschallgerät | |
| EP2101160A4 (de) | Ultraschall-strömungsmesser | |
| ITRE20060026A1 (it) | Apparecchio per trattamenti medicinali | |
| BRPI0613622A2 (pt) | dispositivo médico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20090710 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20100511 |
|
| 17Q | First examination report despatched |
Effective date: 20110120 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| INTG | Intention to grant announced |
Effective date: 20150807 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 775313 Country of ref document: AT Kind code of ref document: T Effective date: 20160315 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602007044929 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2567142 Country of ref document: ES Kind code of ref document: T3 Effective date: 20160420 |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20160421 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: ISLER AND PEDRAZZINI AG, CH Ref country code: CH Ref legal event code: PCOW Free format text: NEW ADDRESS: 1615 W. UNIVERSITY DRIVE, SUITE 132, TEMPE, AZ 85281 (US) |
|
| REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 775313 Country of ref document: AT Kind code of ref document: T Effective date: 20160217 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160518 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160617 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602007044929 Country of ref document: DE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed |
Effective date: 20161118 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160517 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161213 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20071213 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160217 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161213 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20221227 Year of fee payment: 16 Ref country code: NL Payment date: 20221226 Year of fee payment: 16 Ref country code: IE Payment date: 20221227 Year of fee payment: 16 Ref country code: GB Payment date: 20221227 Year of fee payment: 16 Ref country code: FR Payment date: 20221227 Year of fee payment: 16 Ref country code: FI Payment date: 20221227 Year of fee payment: 16 Ref country code: DK Payment date: 20221227 Year of fee payment: 16 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20221227 Year of fee payment: 16 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20230102 Year of fee payment: 16 Ref country code: CH Payment date: 20230109 Year of fee payment: 16 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20221221 Year of fee payment: 16 Ref country code: DE Payment date: 20221228 Year of fee payment: 16 |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230524 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602007044929 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20231231 |
|
| REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231213 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20240101 |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20231213 |
|
| REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20231231 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240101 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240101 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240702 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231213 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231213 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231231 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231231 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231231 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231213 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231213 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231231 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240702 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231231 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231231 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231231 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20250130 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231231 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231214 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231213 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231214 |